Clinical Trial Update: Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating CYP3A4 and CYP1A2 phenotyping to tailor Sunitinib or Erlotinib therapy in cancer patients, including non-small cell lung cancer, renal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Markus Joerger | Conditions: Non Small-cell Lung Cancer, Renal-cell Cancer | Phase 4 | Status: COMPLETED